Figure 3.

HNRNPH1 splicing is independently associated with survival in MCL. (A) Survival data and HNRNPH1 mutation status was obtained for an independent clinical trial cohort (n = 145); cases with HNRPNH1 mutations exhibit significantly worse progression-free survival (n = 8). (B) All MCL cases with available RNA-seq data (n = 103) were classified as having a mutantlike (n = 18) or wild-type (n = 85) HNRNPH1 splicing ratio as in Figure 2E, and OS was plotted. Mutantlike HNRNPH1 splicing was significantly associated with poorer OS. (C) Multivariate Cox proportional modeling was applied to MCL cases with available RNA-seq data (n = 103). TP53 nonsynonymous mutations, HNRNPH1 mutant-like splicing ratio, and blastoid morphology were independently associated with increased hazard.